BTK inhibitor

News

Roche doubles down on BTK with $2.3bn Nurix deal

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.

News

Roche chief medical officer Levi Garraway

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.

Roche doubles down on BTK with $2.3bn Nurix deal

New data build case for Roche's oral BTK drug for MS

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Data builds on Roche's dominance in primary progressive MS

Sanofi gets double blow for MS drug tolebrutinib

Roche's oral MS hope fenebrutinib hits the mark in phase 3

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

BTK inhibitor

Editor's Picks